A new Canadian Journal of Anesthesia meta-analysis ↗ puts a number on the gastric-emptying delay GLP-1 receptor agonists produce, the mechanism that drives both the appetite-suppression effect and the perioperative aspiration-risk concern that anesthesiologists have been warning about for two years. Across 10 prospective studies and 300 patients, GLP-1 RAs prolong gastric emptying half-time by a mean of 74 minutes (95% CI 46-101). Short-acting agents push that to 116 minutes; the early treatment phase (first 10 weeks) sits at 82 minutes.
The methodology. 10 prospective studies (RCTs and prospective cohort studies), 300 total patients, randomized-controlled-trial and observational risk-of-bias assessments per Cochrane and ROBINS-I tools. Multilevel random-effects meta-analysis pooling standardized mean differences. GRADE-rated certainty: very low. PROSPERO-registered protocol (CRD42023461665, first submitted September 2023). The methodology is standard for a perioperative-safety meta-analysis; the very-low certainty rating reflects between-study heterogeneity in measurement methods and patient populations rather than a fundamental problem with the result direction.
The effect sizes worth holding. Overall standardized mean difference of 2.38 (CI 1.05-3.71, p < 0.001), translating to a mean prolongation of 74 minutes. Short-acting GLP-1 RAs (exenatide, lixisenatide) showed a much larger effect: SMD 3.86 (CI 2.37-5.35), prolongation of 116 minutes. Early treatment (under 10 weeks) showed SMD 2.72, prolongation of 82 minutes. The pattern is consistent: maximum gastric-emptying delay early in therapy and with shorter-acting agents, with adaptation reducing the effect over time on long-acting agents like semaglutide ↗.
Why this matters for anesthesia. Aspiration risk during induction of general anesthesia depends on stomach contents at the time of intubation. The standard preoperative fasting guidance (clear liquids 2 hours, light meals 6 hours) assumes normal gastric emptying. A 74-minute mean prolongation, and 116-minute prolongation in some patient populations, means that "fasted" by clock-time may not translate to "fasted" by gastric-content reality for GLP-1 patients. The American Society of Anesthesiologists issued perioperative GLP-1 guidance in 2023 recommending hold periods before elective surgery. The new meta-analysis quantifies the underlying delay that guidance was responding to.
The clinical translation. ASA's current 2023 guidance recommends holding daily GLP-1 RAs the day of surgery and weekly GLP-1 RAs for at least one week before elective surgery. The meta-analysis supports that direction, but the very-low GRADE certainty leaves room for refinement. Two practical implications. First, the first-10-weeks effect being larger than the long-term effect suggests new starters and dose-escalators may need more conservative perioperative planning than established stable-dose patients. Second, the short-acting versus long-acting differential means the same fasting guidance may not be appropriate for both subclasses; patients on exenatide twice daily may need different perioperative timing than patients on semaglutide weekly.
What this is not. A change in the ASA guidance. The meta-analysis is mechanistic data that supports the existing direction; the formal guidance update is the job of the ASA committee, which is the venue where this data will likely enter practice. The very-low certainty rating means the specific minute-prolongation numbers should be read as point estimates with substantial uncertainty rather than precise clinical values. Larger trials, particularly comparing short-acting versus long-acting GLP-1 RAs head-to-head on standardized gastric-emptying protocols, would tighten the estimate.
The platform read. The GLP-1R ↗ target page on peptidemodel anchors the section's metabolic-drug coverage. The gastric-emptying mechanism is the underlying explanation for both the on-label appetite suppression and the perioperative aspiration-risk concern; the news section's coverage of the GI events and treatment-discontinuation cluster in the umbrella review ↗ yesterday referenced this as the dominant adverse-event mode. The same biology that drives weight loss drives the perioperative concern.
What perioperative care has to clarify. Whether the fasting recommendations need modification by GLP-1 subclass (short- versus long-acting), by dose escalation phase (newly started versus stable), or by patient comorbidities (diabetic gastroparesis already present at baseline). Also whether any anesthetic induction adjustments (rapid sequence intubation, gastric ultrasound preassessment) are warranted in higher-risk subgroups. Each is testable, and the meta-analysis is the kind of mechanistic baseline that justifies the next round of perioperative trials.